ArticleThe Journal of urology2009
A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
Article in The Journal of urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Accuracy of novel urinary biomarker tests in the diagnosis of prostate cancer: A systematic review and network meta-analysis.Frontiers in oncology · 2022Pooled it
- Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.PloS one · 2013Pooled it
- Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and In Silico Characterization.Life (Basel, Switzerland) · 2026Article
- AMACR and ZFPL1 serum biomarkers enhance precision in predicting postoperative prostate cancer outcomes.Frontiers in oncology · 2026Article
- AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis.Journal of pathology and translational medicine · 2025Article
- Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer.Biomedicines · 2024Article
- Phytol and its metabolites phytanic and pristanic acids for risk of cancer: current evidence and future directions.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2020Review
- Identification of Clinically Significant Prostate Cancer by CombinedResearch and reports in urology · 2020Article
- Approaches to urinary detection of prostate cancer.Prostate cancer and prostatic diseases · 2019Review
- Long non-coding RNAs and prostate cancer.Cancer science · 2017Review
- Evaluation of Combined Quantification of PCA3 and AMACR Gene Expression for Molecular Diagnosis of Prostate Cancer in Moroccan Patients by RT-qPCRAsian Pacific journal of cancer prevention : APJCP · 2016Article
- Article
- Article
- A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential.Journal of biomarkers · 2014Review
- The present and future of prostate cancer urine biomarkers.International journal of molecular sciences · 2013Review
- PCA3 in the detection and management of early prostate cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Urinary biomarkers for prostate cancer: a review.Asian journal of andrology · 2013Review
- Toward the detection of prostate cancer in urine: a critical analysis.The Journal of urology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeMost men with increased serum prostate specific antigen and negative biopsy require repeat biopsy because of the lack of a sensitive and specific prostate cancer detection test. In this study we evaluated the diagnostic potential of a duplex assay for prostate cancer by quantifying transcript levels of alpha-methylacyl-CoA racemase and prostate cancer antigen 3 in urine sediments following prostatic massage. MATERIALS AND
methodsUrine sediments from 92 patients, 43 with and 49 without prostate cancer, were collected after digital rectal examination. Transcript levels of AMACR, PCA3 and PSA in total RNA isolated from these samples were determined by absolute quantitative real-time polymerase chain reaction. AMACR and PCA3 scores were obtained by normalizing the transcript level to that of prostate specific antigen for each sample and multiplying by 100.
resultsAMACR (p = 0.006) and PCA3 (p = 0.014) scores, but not serum prostate specific antigen (p = 0.306), distinguished specimens from patients with prostate cancer from specimens from patients without prostate cancer, and ROC analysis established the diagnostic cutoff scores for the AMACR and PCA3 tests at 10.7 and 19.9, respectively. As determined from these cutoff scores the AMACR test had 70% (95% CI 56-83) sensitivity and 71% (95% CI 59-84) specificity, whereas the PCA3 test had 72% (95% CI 59-85) sensitivity and 59% (95% CI 45-73) specificity for prostate cancer detection. The combined use of AMACR and PCA3 scores in a dual marker test increased sensitivity to 81% (95% CI 70-93) and specificity to 84% (95% CI 73-94).
conclusionsUrinary AMACR and PCA3 tests were superior to a serum prostate specific antigen test for detecting prostate cancer. Their combined use in a dual marker test further improved sensitivity and accuracy, and could serve as a surveillance test after repeat negative prostate biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.